 |
|
Prolonged Continuous Acyclovir Treatment of Normal Adults With Frequently Recurring Genital Herpes Simplex Virus Infection
Lisa G. Kaplowitz, MD;
David Baker, MD;
Lawrence Gelb, MD;
James Blythe, MD;
Ralph Hale, MD;
Philip Frost, MD;
Clyde Crumpacker, MD;
Sergio Rabinovich, MD;
James E. Peacock, Jr, MD;
James Herndon, MD;
L. Gray Davis, MS, PhD;
the Acyclovir Study Group
JAMA. 1991;265(6):747-751.
Abstract
| |
In this 3-year study of suppressive acyclovir for recurrent genital herpes, patients with more than six recurrences per year were randomized initially to 400 mg of acyclovir or placebo orally two times per day, with recurrences treated with 200 mg of acyclovir five times per day for 5 days. In the second year of the study, all patients received acyclovir as a daily suppressive or intermittent acute therapy; in the third year, all received daily acyclovir. Among 525 patients completing 3 study years, 289 received 3 years of suppressive therapy and 236 received 1 year of acute therapy followed by 2 years of suppressive therapy. Of those who completed the third year, 61% were recurrence free that year; 25% of the suppressive therapy—only group were recurrence free for all 3 years. The annual recurrence rate dropped from more than 12 recurrences per year at baseline to 1.0 (suppressive therapy) and 1.4 (acute and suppressive therapy) recurrences during the third year. No significant toxic effects were detected. Daily suppressive acyclovir therapy was effective and well tolerated.
(JAMA. 1991;265:747-751)
Author Affiliations
From the Medical College of Virginia, Virginia Commonwealth University, Richmond (Dr Kaplowitz); the State University of New York, Stony Brook (Dr Baker); Washington University School of Medicine (Dr Gelb) and St John's Mercy Medical Center (Dr Blythe), St Louis, Mo; the University of Hawaii, Honolulu (Dr Hale); Sinai Medical Center, Miami, Fla (Dr Frost); Beth Israel Hospital, Boston, Mass (Dr Crumpacker); Southern Illinois University School of Medicine, Springfield (Dr Rabinovich); Bowman Gray School of Medicine, Winston-Salem, NC (Dr Peacock); and Burroughs Wellcome Co, Research Triangle Park, NC (Dr Davis). Dr Herndon is in private practice in Dallas, Tex. The members of the Acyclovir Study Group are listed in the acknowledgments.
Footnotes
Reprint requests to Division of Infectious Diseases, Box 49, MCV Station, Richmond, VA 23298-0049 (Dr Kaplowitz).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT
| FULL TEXT
Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT
| FULL TEXT
Long-term Acyclovir Use to Prevent Recurrent Ocular Herpes Simplex Virus Infection
Uchoa et al.
Arch Ophthalmol 2003;121:1702-1704.
ABSTRACT
| FULL TEXT
Reactivation of Genital Herpes Simplex Virus Type 2 Infection in Asymptomatic Seropositive Persons
Wald et al.
NEJM 2000;342:844-850.
ABSTRACT
| FULL TEXT
Clinical Reactivation of Genital Herpes Simplex Virus Infection Decreases in Frequency over Time
Benedetti et al.
ANN INTERN MED 1999;131:14-20.
ABSTRACT
| FULL TEXT
A Large-Scale, Placebo-Controlled, Dose-Ranging Trial of Peroral Valaciclovir for Episodic Treatment of Recurrent Herpes Genitalis
Spruance et al.
Arch Intern Med 1996;156:1729-1735.
ABSTRACT
Long-term Suppression of Recurrent Genital Herpes With Acyclovir: A 5-Year Benchmark
Goldberg et al.
Arch Dermatol 1993;129:582-587.
ABSTRACT
Care of Women Infected With the Human Immunodeficiency Virus
Minkoff and DeHovitz
JAMA 1991;266:2253-2258.
ABSTRACT
LONG-TERM SUPPRESSIVE THERAPY FOR RECURRENT GENITAL HERPES
JWatch General 1991;1991:1-1.
FULL TEXT
|
